A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

BACKGROUND The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris. METHODS We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in native coronary arteries. The trial included 238 patients at 19 medical centers. The primary end point was in-stent late luminal loss (the difference between the minimal luminal diameter immediately after the procedure and the diameter at six months). Secondary end points included the percentage of in-stent stenosis of the luminal diameter and the rate of restenosis (luminal narrowing of 50 percent or more). We also analyzed a composite clinical end point consisting of death, myocardial infarction, and percutaneous or surgical revascularization at 1, 6, and 12 months. RESULTS At six months, the degree of neointimal proliferation, manifested as the mean (+/-SD) late luminal loss, was significantly lower in the sirolimus-stent group (-0.01+/-0.33 mm) than in the standard-stent group (0.80+/-0.53 mm, P<0.001). None of the patients in the sirolimus-stent group, as compared with 26.6 percent of those in the standard-stent group, had restenosis of 50 percent or more of the luminal diameter (P<0.001). There were no episodes of stent thrombosis. During a follow-up period of up to one year, the overall rate of major cardiac events was 5.8 percent in the sirolimus-stent group and 28.8 percent in the standard-stent group (P<0.001). The difference was due entirely to a higher rate of revascularization of the target vessel in the standard-stent group. CONCLUSIONS As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.

[1]  L. Campeau.  Letter: Grading of angina pectoris. , 1976, Circulation.

[2]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[3]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[4]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[5]  Larry S. Dean,et al.  Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.

[6]  D. Baim,et al.  Novel approach to the analysis of restenosis after the use of three new coronary devices. , 1992, Journal of the American College of Cardiology.

[7]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[8]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[9]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[10]  M. Leon,et al.  Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.

[11]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[12]  L Chiariello,et al.  A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. , 1997, The New England journal of medicine.

[13]  R A Schatz,et al.  Catheter-based radiotherapy to inhibit restenosis after coronary stenting. , 1997, The New England journal of medicine.

[14]  Samin K. Sharma,et al.  Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) , 1998, Circulation.

[15]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[16]  C. Wegner,et al.  Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. , 1999, Journal of cardiovascular pharmacology.

[17]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[18]  Vos,et al.  Anti-restenosis Trials. , 2000, Current interventional cardiology reports.

[19]  A. Kastrati,et al.  Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. , 2000, Circulation.

[20]  G. Stone,et al.  Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. , 2000, Circulation.

[21]  P. Serruys,et al.  Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement , 2000, Circulation.

[22]  C. Di Mario,et al.  Randomized Comparison of Coronary Stent Implantation Under Ultrasound or Angiographic Guidance to Reduce Stent Restenosis (OPTICUS Study) , 2001, Circulation.

[23]  S. Marx,et al.  Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.

[24]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[25]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[26]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[27]  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001 .

[28]  Lawrence M. Friedman,et al.  Data and Safety Monitoring Boards , 2002 .